Markets

AmSurg (AMSG) Poised on Strong Pipeline, Strategic Buyouts

On Nov 12, 2015, we issued an updated research report on AmSurg CorporationAMSG , a leading operator of single-specialty practice-based ambulatory surgery centers (ASCs).

AmSurg delivered a solid third-quarter 2015, beating the Zacks Consensus Estimate on both lines. The outperformance was driven by successful execution of the company's organic growth and acquisition strategies in both its Ambulatory and Physicians Services businesses.

AmSurg has made consistent progress with several quarters of double-digit sales growth. Significant contribution from Sheridan Healthcare, which recorded its fourth full quarter as part of AmSurg's business, drove the company's third-quarter revenues. It also demonstrated strong growth across all categories. According to the company, the combination of Sheridan's position in outsourced physician services and AmSurg's leadership in ambulatory services has been received well in the niche markets and has generated a strong pipeline of cross-selling opportunities.

Meanwhile, the domestic development pipeline at AmSurg remains robust. Additionally, the company's center acquisition pipeline has regained momentum. Currently, the company is identifying acquisition opportunities for anesthesia, emergency, radiology and neonatology as well as discovering new ASC acquisition opportunities. During the third quarter, the company acquired two ASCs and opened one de novo center. It has also acquired two additional multi-specialty ASCs subsequent to the end of the third quarter.

Moreover, solid third-quarter growth and an impressive pace of acquisitions have encouraged management to raise AmSurg's 2015 guidance indicating the presence of some near-term catalyst that will aid financials in the near future. We are also optimistic about the government agencies' initiatives to curtail healthcare expenses, leading to a shift toward ambulatory services business.

Zacks Rank

Amsurg presently carries a Zacks Rank #1 (Strong Buy). Other stocks worth considering in the same sector include LHC Group, Inc. LHCG , Foundation Healthcare, Inc. FDNH and Amedisys Inc. AMED . While LHCG and FDNH sport a Zacks Rank #1, AMED holds a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMEDISYS INC (AMED): Free Stock Analysis Report

AMSURG CORP (AMSG): Free Stock Analysis Report

LHC GROUP LLC (LHCG): Free Stock Analysis Report

FOUNDATION HLTH (FDNH): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AMED LHCG

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More